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ABSTRACT
Introduction Squamous cell carcinoma of the anus 
is a common cancer among sexual minority men, 
especially HIV- positive sexual minority men; however, 
there is no evidenced- based national screening protocol 
for detection of anal precancers. Our objective is to 
determine compliance with annual anal canal self- 
sampling or clinician- sampling for human papillomavirus 
(HPV) DNA.
Methods and analysis This is a prospective, randomised, 
two- arm clinical study to evaluate compliance with annual 
home- based versus clinic- based HPV DNA screening of 
anal canal exfoliated cells. The setting is primary care 
community- based clinics. Recruitment is ongoing for 
400 HIV- positive and HIV- negative sexual minority men 
and transgender persons, aged >25 years, English or 
Spanish speaking, no current use of anticoagulants other 
than nonsteroidal anti- inflammatory drugs and no prior 
diagnosis of anal cancer. Participants are randomised 
to either receive a swab in the mail for home- based 
collection of an anal canal specimen at 0 and 12 months 
(arm 1) or attend a clinic for clinician collection of an anal 
canal specimen at 0 and 12 months (arm 2). Persons 
will receive clinic- based Digital Anal Rectal Examinations 
and high- resolution anoscopy- directed biopsy to assess 
precancerous lesions, stratified by study arm. Anal 
exfoliated cells collected in the study are assessed for 
high- risk HPV persistence and host/viral methylation. The 
primary analysis will use the intention- to- treat principle to 
compare the proportion of those who comply with 0- month 
and 12- month sampling in the home- based and clinic- 
based arms. The a priori hypothesis is that a majority of 
persons will comply with annual screening with increased 
compliance among persons in the home- based arm versus 
clinic- based arm.
Ethics and dissemination The study has been approved 
by the Medical College of Wisconsin Human Protections 
Committee. Results will be disseminated to communities 
where recruitment occurred and through peer- reviewed 
literature and conferences.
Trial registration number NCT03489707.
INTRODUCTION
Persistent infection with high- risk human 
papillomavirus (hrHPV) is virtually a neces-
sary cause of squamous cell carcinoma of 
the anus (SCCA).1 In the USA, incidence 
of and mortality from SCCA has increased 
in recent decades,2 and is now a common 
cancer among sexual minority men (SMM) 
especially HIV- positive SMM among whom 
incidence is 40- fold to 50- fold higher than 
in persons overall.3–5 Since it will be decades 
before the benefits of HPV vaccines are fully 
realised,6 screening for anal precancers and 
invasive disease is needed.
Screening may include Digital Anal Rectal 
Examinations (DARE) for early detection of 
invasive SCCA among HIV+ SMM,7 while Pap 
cytology and biopsy- directed high- resolution 
anoscopy (HRA) have been used to identify 
precancerous lesions8 9; however, there is 
Strengths and limitations of this study
 ► This trial will randomise 400 persons at increased 
risk for anal cancer to home- based or clinic- based 
collection of anal canal exfoliated cells at 0 and 
12 months to determine preference for either the 
home- based or clinic- based collection.
 ► Persons in the clinic- based arm may choose to at-
tend any one of the five geographically dispersed 
clinics in a medium size, US city.
 ► At study end, all persons will be asked to receive 
high- resolution anoscopy to allow assessment of the 
association between high- risk human papillomavi-
rus persistence and precancerous lesions.
 ► Recruitment into this trial is by convenience sample 
and, thus, enrollment may favor persons concerned 
about anal cancer.
2 Nyitray AG, et al. BMJ Open 2021;11:e051118. doi:10.1136/bmjopen-2021-051118
Open access 
no consensus on the optimal screening strategy and few 
HIV+ SMM are screened.10
Cervicovaginal self- sampling increases use of cervical 
cancer screening and a similar approach may be useful 
for anal cancer screening.11 12 SMM are able to self- sample 
the anal canal and find it acceptable.13–16 Self- sampling 
may also address healthcare access barriers like embar-
rassment with anogenital physical examinations,17 or a 
history of poor healthcare due to having a minority sexual 
orientation,18 in addition to barriers to cancer screening 
imposed by the COVID-19 pandemic.19 However, there are 
few empirical data that assess return rates of home- testing 
swabs among SMM20–22 and, to our knowledge, none that 
also report the adequacy of the specimen for HPV DNA 
genotyping (table 1). Furthermore, transgender individ-
uals who share behavioural risk factors for hrHPV with 
SMM may uniquely benefit from self- sampling options 
(eg, reduced gender discordance).23
In addition, there are no data on acceptability when 
anal cancer screening methods are repeated over time. 
Although one- time HPV DNA screening is of little or 
no value for SMM given hrHPV prevalence that often 
exceeds 50%,24 25 annual repeated screening allows detec-
tion of persons with potentially clinically relevant hrHPV 
persistence who are at increased vulnerability for anal 
high- grade squamous intraepithelial lesions (HSILs).26 
Other biomarkers may also have utility in anal cancer 
screening including DNA methylation testing of HPV 
and human genes. Methylation patterns of host and 
virus accurately predict cervical HSIL, but are much less 
studied for anal HSIL.27 28
This study protocol is designed to test approaches 
that may inform future screening programmes. These 
approaches are focused on the following 4 of 10 
screening characteristics that are considered essential 
for successful public health screening programmes29: (1) 
using a screening method that is acceptable, (2) using the 
screening method repeatedly, (3) having a suitably sensi-
tive and specific test for detecting disease and (4) having 
a test that is considered cost effective.
Primary objective
To determine compliance with annual anal canal 
self- sampling or clinician- sampling for HPV among 
Milwaukee, Wisconsin HIV+ and HIV– SMM and trans-
gender persons, aged >25 years.
We hypothesise that a majority of persons will comply 
with annual screening with increased compliance among 
persons in the home- based arm versus clinic- based arm.
Secondary objectives
 ► To determine estimates of the relative ability of 
home- based screening to increase annual screening 
compliance.
 ► To estimate the influence that home- based versus 
clinic- based screening has on the uptake of HRA- 
directed biopsy.
 ► To estimate the cross- sectional association between 
hrHPV persistence and detection of anal high- grade 
squamous epithelial lesions.
 ► To estimate the association between host and viral 
genome methylation patterns and detection of anal 




This is a prospective, randomised, two- arm clinical study 
to evaluate compliance with annual home- based versus 
clinic- based sampling of anal canal exfoliated cells for 
DNA- based testing among HIV+ and HIV– SMM and 
transgender persons. At study entry, persons randomised 
to arm 1 will receive a home- based collection swab in the 
mail at 0 and 12 months, and those randomised to arm 
2 will attend a clinic where a clinician will collect the 
exfoliated cell specimen at 0 and 12 months. Then, all 
persons will receive a clinic- based HRA- directed biopsy 
to assess precancerous lesions by study arm. Study start 
date was 12 March 2019. The study is currently recruiting 
participants. Study enrollment began 9 January 2020, was 
suspended due to the COVID-19 pandemic on 14 March 
2020 and then resumed on 3 November 2020. Study 
completion date is 31 August 2022.
Study setting
The Prevent Anal Cancer (PAC) Self- Swab Study is based 
in Milwaukee, Wisconsin, a Midwest US city with a metro 
population of 1.6 million. The city of Milwaukee is racially 
and ethnically diverse with 46.0% of the population 
white, 39.2% black and 18.2% Latino according to the US 
census 2015 estimate.
The trial will use the existing healthcare infrastructure 
in Milwaukee. Persons enrolled in the study can choose 
to attend one of the five geographically dispersed clinics 
in the Milwaukee area for anal canal sampling. Each 
participating clinic has a history of providing special-
ised medical care to SMM, transgender persons and/or 
persons with HIV.
Eligibility criteria
Inclusion criteria: Persons will be Milwaukee metro- area 
residents and >25 years of age. There is no upper age 
limit. Persons must identify as SMM or a transgender 
person who has sex with men and speak either Spanish 
or English. Persons are included without regard to anal 
cancer screening history, HIV status or HPV vaccination 
status.
Exclusion criteria: Persons are excluded if they report 
a prior diagnosis of anal cancer, the use of clopidogrel, 
warfarin, apixaban or another anticoagulant other than 
aspirin or non- steroidal anti- inflammatory drugs, a diag-
nosis of haemophilia, cirrhosis with bleeding varices or 
thrombocytopenia. Persons are also excluded if they are 
not willing to attend one of the five study clinics or have 
plans to move away from Milwaukee in the next year.
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Participant recruitment
Persons in Milwaukee are encouraged to join a study 
of anal cancer screening, with no mention of self- 
sampling, to attract participants who may have diverse 
views about self- sampling. Study recruitment uses conve-
nience sampling using the following strategies: (1) social 
media advertisements to reach persons outside of clinics 
and thus possibly benefitting more from home- based 
screening30; (2) recruitment in clinics that serve SMM 
and transpersons, (3) distribution of promotional mate-
rials in targeted businesses and non- profits; (4) a referral 
programme whereby enrolled participants receive incen-
tives to recruit partners, friends and family; (5) word of 
mouth and (6) presentations to community groups. All 
persons are directed to a short online survey that assesses 
eligibility and basic demographics. The study’s recruit-
ment targets are a minimum of 50% of participants will 
be HIV- positive, the median age will be ~50 years, and the 
racial and ethnic composition will reflect the population 
of Milwaukee.
Randomisation
Immediately after enrollment, persons are randomised in 
a 1:1 allocation to either the home- based or clinic- based 
sampling using a study- generated randomisation table 
within Research Electronic Data Capture (REDCap) 
(Vanderbilt University) which assigns a study arm to each 
participant. Given obvious differences of each arm, rando-
misation cannot be blinded to study staff or participants.
Interventions
At baseline, persons randomised to the intervention arm 
are mailed a ‘PAC Pack’ to their home which is a package 
lined with foam that contains supplies for self- sampling 
(figure 1). The PAC Pack design was informed by a 
community advisory board and was pilot tested. It includes 
a FLOQSwab (Copan Italia, Brescia, Italy), a vial of 2.0 mL 
of Standardized Transport Medium (STM; Digene Corpo-
ration), a biohazard bag, gloves and a device to record 
ambient temperature (LogTag Recorders, Auckland, 
New Zealand) and instructions for self- sampling based 
on the Darragh and Winkler31 protocol for anal canal 
sampling. Participants immediately immerse the used- 
swab in the vial of STM and are asked to return the swab 
as soon as possible. Return overnight postage is included 
for shipment to the Medical College of Wisconsin Tissue 
Bank. One week after the PAC Pack is sent to participants, 
they are reminded, via preferred method of communica-
tion (eg, text or email), to use and return the PAC Pack, 
after which an online computer- assisted self- interview 
(CASI)32 33 assesses participants’ acceptability of the PAC 
Pack.
Figure 1 Study activity: home and clinical flow activities. DARE, Digital Anal Rectal Examinations; HPV, human papillomavirus; 
HRA, high- resolution anoscopy; PAC, Prevent Anal Cancer.
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At baseline, persons randomised to the control arm 
are asked to make an appointment at a participating 
study clinic for anal canal sampling. PAC study appoint-
ments can be scheduled throughout the week at times 
that are convenient to the participant. The attending 
clinician (either a physician or nurse) collects exfoli-
ated cells with the same flocked swab as used in the PAC 
Pack while also using the Darragh and Winkler sampling 
protocol (eg, twirling the swab, counting slowly to 10 and 
applying pressure to the anal canal walls) in addition to 
performing a DARE.31 34 Participants are encouraged at 
the clinic to take advantage of other clinic services like 
sexually transmitted infection testing and HPV vaccina-
tion. Participants then assess clinician sampling accept-
ability using a CASI. The swab is then transported to a 
laboratory for processing and storage until biomarker 
assessment.
Twelve months after baseline, persons again complete 
the same primary study activities assigned to them at 
randomisation, that is, mailed a PAC Pack or asked to 
attend a clinic for sampling regardless of their compli-
ance with study activities at baseline. In between the 
baseline and 12- month study activities, study staff contact 
participants in ways typical of medical clinics (eg, to send 
birthday greetings). We chose annual screening based 
on our studies estimating that 12% of SMM will have 
12- month persistence with hrHPV (suggesting increased 
risk for anal cancer and thus needed HRA),35 expert 
opinion on anal screening intervals for HIV+ SMM,36 and 
because it is a familiar interval that may encourage repeat 
screening.
After 12- month study activities, all persons are asked to 
schedule an HRA regardless of compliance with home- 
based sampling or clinic- based sampling. All suspicious 
lesions are documented and biopsied. If no lesions are 
seen on HRA, then two biopsies are taken from two 
quadrants of the anal canal to assess sensitivity of the 
anoscopist’s negative findings. All anal biopsies will be 
interpreted by a single experienced pathologist using a 
two- tiered system (low- grade squamous intraepithelial 
lesion and HSIL, and further classified by the applicable 
anal intraepithelial neoplasia (AIN) subcategorisation 
(AIN1, AIN2 and AIN3) with subsequent p16 staining as 
necessary.37
Clinician training
Physicians and nurses seeing study participants complete 
mandated in- person training in anal canal sampling31 
and DARE34 led by a nurse practitioner and the principal 
investigator. In addition to anal swab and DARE tech-
nique and documentation, clinicians are trained in anal 
cancer epidemiology and study objectives. The training 
includes DARE practice on a task mannequin (Kyoto 
Kagaku, Kyoto, Japan). HRA- directed biopsies at the 
Medical College of Wisconsin/Froedtert Anal Dysplasia 
Program are performed by the nurse practitioner with 
advanced HRA training and >300 HRAs completed.
Computer-assisted self-interviews
CASI data in English and Spanish are collected at four 
timepoints (study start, postbaseline swab, post 12- month 
swab and post- HRA) to provide data about modifiable and 
non- modifiable factors associated with annual screening. 
CASI items include questions about anal cancer suscepti-
bility, PAC Pack and clinician screening acceptability, HRA 
acceptability, screening self- efficacy and anxiety, medical 
history, sexual behaviour, substance use, measures to 
inform cost- effectiveness and the COVID-19 pandemic. 
When possible, questions were adapted from validated 
cervical cancer screening instruments within the frame-
work of Health Belief Model constructs38 like perceived 
susceptibility for anal cancer and barriers to and bene-
fits of anal cancer screening. CASIs were refined through 
cognitive interviews and pilot testing.
Participants receive US$35 for completion of the base-
line activities, US$45 for 12- month activities and US$50 
for HRA.
Biomarker testing
Swab specimens transported to the Medical College of 
Wisconsin Tissue Bank are processed and then aliquoted 
into cryovials for transport to laboratories for genotyping 
and methylation testing. Cryovial specimens are blinded 
as to study arm.
HPV genotyping: At the Moffitt Cancer Center and 
Research Institute, DNA will be extracted from all spec-
imens using the robotic MDx Media Kit (Qiagen), 
according to the manufacturer’s instructions. The HPV 
SPF10 PCR- DEIA- LiPA line probe assay system is used to 
detect 25 HPV genotypes by reverse hybridisation tech-
nology: HPV6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 
45, 51, 52, 53, 54, 56, 58, 59, 66, 68/73, 70 and 74. Positive 
(CaSki and SiHa) and negative controls (C33A) are used 
during genotyping along with detection of human beta- 
globin to assess specimen adequacy.39
To avoid persistence misclassification, persons with 
hrHPV type- specific concordance at 0 and 12 months 
have specimens classified according to HPV- type variant 
at the Molecular Biology Laboratory, Centre of Transla-
tional Oncology, Instituto do Câncer do Estado de São 
Paulo, São Paulo, Brazil.40 41 HPV variants differ by muta-
tions in specific positions within the viral DNA. Thus, 
HPV variant analysis will be performed by sequencing of 
viral DNA fragments amplified by PCR.
At Queen Mary University of London methylation 
assessment of the host tumour suppressor gene EPB41L3 
will be done for all specimens regardless of HPV geno-
type positivity while all specimens that are hrHPV+ will 
also be assessed for viral methylation patterns. Assessment 
of methylation will be performed using sodium bisulfite 
conversion (EZ DNA Methylation Kit, Zymo Research, 
CA, USA) and pyrosequencing. Specimens will be eval-
uated using the S5 classifier DNA methylation panel42 
with the S5 score determined using a weighted average of 
DNA methylation scores from CpG regions on EPB41L3 
and HPV16, 18, 31 and 33 late regions.28
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Clinical management
Regardless of study arm, participants receive a DARE at 
study start to rule out palpable masses or other symptoms 
that may indicate malignancy. Anal canal and perianal 
symptoms are recorded on standardised forms. During 
DARE and HRA procedures, standard clinic protocol 
is used for treating and/or referring for follow- up all 
persons with suspicious lesions or symptoms.
DNA testing for anal precancer screening is not 
approved at this time by the US Food and Drug Administra-
tion (FDA) and is rarely used in clinics to screen patients. 
This is especially true for high- risk populations like SMM 
given their high prevalence of anal HPV which results in 
low specificity for one- time HPV DNA screening43; thus, 
genotyping results are not given to participants with 
the following exception: participants with type- specific, 
persistent infection with a hrHPV genotype, as indicated 
by genotyping tests at both baseline and at 12 months, will 
be notified by the clinician and counselled to adhere to 
regular contact with a knowledgeable physician to assess 
future anal cancer risk. Methylation assay results will be 
compared with HPV testing performance and for their 
ability to detect high- grade lesions but will not inform 
clinical management.
Outcome measures
The primary endpoint is the return of a completed PAC 
Pack or the completion of a clinic visit at both baseline 
and 12 months. The secondary outcome measures are 
as follows: (1) factors associated with screening compli-
ance at baseline and 12 months, (2) attendance at an 
HRA appointment, (3) the association between hrHPV 
persistence and HSIL and (4) the association between 
host/viral methylation and HSIL.
Power
Our primary outcome is compliance with sampling at both 
baseline and 12 months. We will compare the proportion 
of persons in compliance in the home- based arm and in 
the clinic- based arm using a Mantel- Haenszel test for differ-
ence in proportions in a stratified design. Assuming 200 
persons in each arm, we can approximate a lower bound 
for our power assuming a χ2 distribution with 1 degree of 
freedom.44 We estimate 10% loss to follow- up (eg, moving 
away) at 12 months (n=180) and 80% of persons will 
return a home- collected swab (144) for 72% compliance 
at 12 months (ie, 144/200).20 Using the same algorithm 
with cervical cancer screening compliance data,45 we esti-
mate 70% of clinic- based attendees at baseline and 60% at 
12 months also with 10% loss to follow- up (200×0.9=180; 
180×0.60=108 or 108/200=54% compliance). Using intent 
to treat, if 144 home- collected swabs (72%) and 108 clinic- 
collected swabs (54%) are returned at 12 months, and 
assuming two- sided tests and α of 0.05, we have 84% power 
to detect a difference (0.18) between arms (table 2).
Data plan
Data collection: Data are collected through (1) partic-
ipant completion of CASIs; (2) staff recording of 
participant biometrics and (3) clinician recording of 
anal sampling and DARE results. CASIs are used during 
eligibility screening, at baseline, postsampling at 0 and 12 
months (home and clinic), and post- HRA.
Data analysis: Our primary analysis is to compare 
the proportion of those who comply with 0- month and 
12- month sampling in the home- based and clinic- based 
arms. Our primary endpoint, compliance, is categorised 
as ‘Yes’ if a swab is returned at 0 and 12 months and ‘No’ 
otherwise. The proportion of PAC Packs and clinic visits 
completed at 1, 3 and 6 months after the 0- month and 
12- month timepoint will be assessed. The null hypothesis 
is that the proportion of those complying in each arm is 
the same with assessment by a Mantel- Haenszel test for 
difference in proportions. After randomisation, persons 
randomised to arm 1 who ‘crossover’ and attend a doctor’s 
visit for anal cancer screening, including DNA collection, 
without returning a home- base PAC Pack, will be counted 
as non- compliant. Under the intention- to- treat principle, 
all participants who are randomised are included in the 
analyses (both primary and exploratory). For sensitivity 
analysis, per protocol analysis will be performed with 
data from compliant participants. Compliance can be 
estimated without dependence on specimen adequacy or 
compliance with HRA.
To determine Health Belief Model constructs, for 
example, self- efficacy, that are associated with compli-
ance, purposeful modelling strategies will be employed.46 
Bivariate logistic regressions will be performed for each 
factor, and those factors with a p value <0.25 in the bivar-
iate analysis will be included in a multivariable logistic 
regression model. Intermediate variables will be excluded 
from multivariate modelling in Aim 2.47 Associations in 
the multivariable model will be considered significant 
with a p value of <0.05. Adjusted and unadjusted ORs will 
be reported with 95% CIs. We will regress compliance on 
covariates after adjusting for potential confounders iden-
tified with directed acyclic graphs.48
The COVID-19 pandemic is a potential confounder of 
the association between perceived anal cancer suscepti-
bility and intentions to screen for anal cancer because 
COVID-19 may affect a person’s perceived susceptibility 
for diseases like anal cancer while COVID-19- induced 
changes in healthcare may, for example, boost home- 
based screening or add barriers to clinic attendance; 
thus, the association between perceived anal cancer 
susceptibility and intentions to screen for anal cancer 
Table 2 Power to detect difference in proportion of DNA 




clinic samples Difference Power
0.63 0.43 0.20 0.89
0.72 0.54 0.18 0.84
0.70 0.56 0.14 0.63
0.65 0.52 0.13 0.55
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may not be understood without adjustment for the threat 
of COVID-19 (figure 2).
Data security: CASI data are collected in REDCap 
which is a Health Insurance Portability and Account-
ability Act (HIPAA)- compliant platform. All hard copy 
data are kept in locked file cabinets in secure buildings. 
The final dataset for analysis will be de- identified and 
published in aggregate so confidentiality is protected. 
Fully de- identified datasets will be shared with properly 
trained investigators after assessment of institutional poli-
cies, Medical College of Wisconsin Human Protections 
Committee rules, as well as local, state, and Federal laws 
and regulations.
Ethics and dissemination
Persons not eligible are provided anal cancer educational 
resources (eg, https:// analcancerinfo. ucsf. edu/). As a 
result of the COVID-19 pandemic, study activities previ-
ously conducted face- to- face were moved online when-
ever possible including consenting and surveys. A written 
consent form is used by trained staff and emphasises that 
(1) there is no FDA- approved HPV test for anal cancer 
screening; (2) persons will not be notified of baseline 
HPV DNA genotyping results due to high cross- sectional 
prevalence24 and (3) persons will be made aware of results 
after the 12- month swab and HRA if there is evidence 
of 12- month high- risk persistence. Safety monitoring 
of participants is conducted by clinicians and staff. The 
low- risk of the study activities to participants does not 
necessitate a data monitoring committee. This protocol 
is version 4.0 and was approved by the Medical College 
of Wisconsin Human Protections Committee. Protocol 
modifications which may impact on the conduct of the 
study, potential benefit of the participant or may affect 
participant safety, including changes of study objectives, 
study design, participant population, sample sizes, study 
procedures or significant administrative aspects require 
a formal amendment to the protocol. Study findings 
will be disseminated to communities where recruitment 
occurred and through peer- reviewed literature and 
conferences.
Patient and public involvement
Given that neither the feasibility of a mailed HPV self- 
sampling kit nor the optimal form and procedures 
for such a kit have been established, we employed a 
10- member community advisory board (CAB) for guid-
ance.49 Comprised of both HIV- positive and HIV- negative 
members of the study population, the CAB advised on the 
cultural competency of study materials for middle- aged, 
older and racial and ethnic minority SMM and transper-
sons. After training on anal cancer and study objectives, 
the CAB meets at least quarterly and provides guidance 
on recruitment, recruitment materials, internet webpage 
design, kit design, kit dissemination and interpretation 
of results.
DISCUSSION
The annual incidence of SCCA among HIV- positive and 
HIV- negative SMM is approximately 85/100 000 and 
19/100 000, respectively.3 In comparison, the current 
incidence of cervical cancer is approximately 7/100 000 
in countries with established cervical cancer screening 
programmes.50 Given this achievement and given the 
same pathogens (and similar epidemiology, cytology 
and histology), initial anal cancer screening modalities 
have mimicked cervical cancer screening approaches51; 
however, while it would be optimal to detect precancers, 
rather than early invasive cancer, the success of this model 
is not certain. Indeed, the success of cervical cancer 
programmes is uneven with high rates of cervical cancer 
persisting in some high- resource countries, for example, 
in Eastern Europe.50 Thus, the success of an anal cancer 
model that mimics a cervical cancer model is not assured, 
especially in the context of the lack of current infrastruc-
ture for the model, for example, limited availability of 
HRA.
Although HPV testing is replacing cervical cancer Pap 
testing,52 HPV testing for anal cancer screening among 
SMM is often dismissed as lacking specificity given that 
half or more of SMM may already harbour HPV; however, 
screening for common cancers like cervical cancer or 
colorectal cancer is usually a repeated affair. Repeated 
HPV testing may be an acceptable screening feature 
among persons at increased vulnerability to anal cancer 
and may also support increased specificity for HSIL 
through the detection of persistence; however, the lack 
of utility for a one- time HPV test and the importance of 
Figure 2 Confounding by perceived susceptibility to COVID-19.
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HPV persistence in a screening programme will require 
education for persons who screen.
There has been little investigation of DNA testing 
for anal cancer screening even though DNA tests are 
increasingly used in cervical cancer screening.53 54 The 
movement to DNA tests also provides increased oppor-
tunity for self- screening since self- collected specimens 
better support DNA assessment compared with cyto-
logical assessment, that is, compared with Pap cytology, 
DNA assessment is more sensitive for high- grade cervical 
precancer detection.52 Home- based, self- swab programs 
may also increase access for those less likely to visit clinics 
and are cost- effective55–57; thus, our hypothesis recog-
nises the tendency of some to avoid doctors and avoid 
anogenital examinations, for example, due to embarrass-
ment.17 18 58 59
Current assessments of anal cancer screening options 
may support subsequent programmes that are more 
robust. To inform future policy, this protocol can assess 
some of these options including individual preference 
for self- screening or clinician screening, individual 
competency in collecting adequate specimens, home- 
based versus clinic- based screening impact on subse-
quent follow- up with HRA, and the association of two 
biomarkers, HPV persistence and host- viral methylation 
to assess risk for HSIL.
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